Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: stevie who wrote (169)	2/26/1999 2:23:00 PM
From: Walter Amstutz	Read Replies (1) \| Respond to of 377

Wire: ISDN DateStamp: 990226 13:30:17 Corporation: VASOGEN INC. Stock Symbol: VAS Dateline: MISSISSAUGA, ONTARIO Headline: VASOGEN COMPLETES SPECIAL WARRANT ISSUE Text: Vasogen Inc. (ME:VAS) is pleased to announce that it has completed a private placement of 5,000,000 special warrants at a price of $1.55 per special warrant. Net proceeds after expenses related to the issue are $7.1 million. Loewen, Ondaatje, McCutcheon Limited, BLC Securities Inc. and Research Capital Corporation acted as agents. Each special warrant is exchangeable without further payment into one common share. The proceeds of the issue are being held in escrow pending clearance by the Company of a prospectus, filed by the Company today, prior to June 22, 1999. The net proceeds will be used to fund the Vasogen”s research and development program and corporate activities. The Company”s projected cash resources as at February 28, 1999, taking these proceeds into account, total $11.6 million. Vasogen is focused on advancing the treatment of cardiovascular and autoimmune diseases through the development and commercialization of patient-specific therapies. These therapies use a patient”s own blood to regulate the immune processes involved in these diseases. Patient-specific therapies are designed to target fundamental disease-causing events, providing safe, effective treatment. INVESTOR CONTACT Trevor Burns Investor Relations tel (905) 569-9065 e-mail investor@vasogen.com 2155 Dunwin Drive, Suite 10 Mississauga, ON, Canada L5L 4M1 tel (905) 569-2265 fax (905) 569-9231 vasogen.com